Skip to main content
Caplight Logo









Shanghai Unicar-Therapy Bio-medicine Technology

Shanghai Unicar-Therapy Bio-medicine Technology

Private
ShanghaiHealthcare & Life Scienceshttp://www.unicar-therapy.com/

Last Round

Series C

Aug 26, 2022

Total Funding Raised

$8.2M

Company Overview

Shanghai Unicar-Therapy Bio-medicine Technology is a biotechnology company that develops cellular immunotherapy drugs and CAR-T therapies for oncology treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

CAR-T cell therapyimmunotherapycancer immunotherapycell therapyoncologybiotechdrug discoverybiopharmaceuticalsolid tumor therapyhematological malignanciesgene regulationantibody discoveryclinical trialsprecision medicinenext-gen CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Unicar-Therapy Bio-medicine Technology Comparables

Compare Shanghai Unicar-Therapy Bio-medicine Technology with similar companies based on industry and business-model similarity.

Shanghai Unicar-Therapy Bio-medicine Technology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Juventas Cell Therapy Ltd.
88%
Shanghai YaKe Biotechnology Co., Ltd.
88%
Chongqing Precision Biotech Co., Ltd.
88%

Shanghai Unicar-Therapy Bio-medicine Technology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CAug 26, 2022
Series BMar 30, 2021
Series AJun 1, 2019
AngelMar 1, 2016

Shanghai Unicar-Therapy Bio-medicine Technology Investors

Notable investors and investment history

Shanghai Unicar-Therapy Bio-medicine Technology investors
InvestorRounds
Alwin CapitalSeries A
Junci InvestmentSeries C
Apricot CapitalAngel

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2022

    Raised $4M with Junci Investment participating

  • Jun 1, 2019

    Raised Series A with Alwin Capital and Hainan Haiyao Co Ltd.

Shanghai Unicar-Therapy Bio-medicine Technology Filings

Explore SEC and related filing metadata, where available.

Shanghai Unicar-Therapy Bio-medicine Technology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Shanghai Unicar-Therapy Bio-medicine Technology's valuation, stock price, and market status.

Is Shanghai Unicar-Therapy Bio-medicine Technology a public or private company?

Shanghai Unicar-Therapy Bio-medicine Technology is a private company.

What is the current stock price of Shanghai Unicar-Therapy Bio-medicine Technology?

Shanghai Unicar-Therapy Bio-medicine Technology is a private company with no public stock price. Caplight tracks Shanghai Unicar-Therapy Bio-medicine Technology's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Shanghai Unicar-Therapy Bio-medicine Technology worth (valuation)?

Valuation information for Shanghai Unicar-Therapy Bio-medicine Technology is not publicly available.

Can I buy Shanghai Unicar-Therapy Bio-medicine Technology stock?

Shanghai Unicar-Therapy Bio-medicine Technology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Shanghai Unicar-Therapy Bio-medicine Technology's last funding round?

Shanghai Unicar-Therapy Bio-medicine Technology's most recent funding round was Series C on August 26, 2022.

Who are the main investors in Shanghai Unicar-Therapy Bio-medicine Technology?

Key investors in Shanghai Unicar-Therapy Bio-medicine Technology include Alwin Capital, Junci Investment, Apricot Capital.

Will Shanghai Unicar-Therapy Bio-medicine Technology IPO soon?

No public IPO plans have been announced for Shanghai Unicar-Therapy Bio-medicine Technology.

How can I track Shanghai Unicar-Therapy Bio-medicine Technology secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Shanghai Unicar-Therapy Bio-medicine Technology's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersShanghai
Employee Range12
Year Founded2015
Last FundingAug 26, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?